Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension
https://doi.org/10.15829/1728-8800-2011-6-24-29
Abstract
Aim. To assess the potential of the angiotensin II receptor antagonist losartan for the correction of hyperuricemia (HU) in patients with arterial hypertension (AH) and metabolic syndrome (MS).
Material and methods. This open, randomised, controlled comparative study in parallel groups included 60 AH patients with MS and HU. The patients received losartan or standard therapy for 12 weeks.
Results. Throughout the follow-up period, no significant difference in antihypertensive effect was observed between the losartan and standard therapy groups. Losartan group patients demonstrated a more pronounced decrease in uric acid levels (-34,7 % vs. -7,8 % in the standard therapy group; p<0,05). In addition, losartan therapy, compared to the standard treatment, was associated with improved vascular elasticity, as manifested by the pulse wave velocity decrease (-27,8 % vs. -8,1 % for carotid-femoral index, and -30,2 % vs. -12,6 % for carotidradial index, respectively; both p<0,05).
About the Authors
S. V. Nedogoda
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
E. V. Chumachok
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
A. A. Ledyaeva
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
V. V. Tsoma
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
References
1. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 3: 369-79.
2. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002;2:126-30.
3. Athyros VG, Elisaf M., Papageorgiou A. A. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREck Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
4. Bairaktari ET, Kakafika AI, Pritsivelis N, Hatzidimou KG, Tsianos EV, Seferiadis KI, et al. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis 2003;41:1225-32.
5. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg. Sweden Acta Med Scand 1988;224:549-55.
6. Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J 1975;37:1210-5.
7. Daijiro U, Hiroaki K. Long-term effects of angiotensin II receptor antagonist losartan on uric acid metabolism in hyperuricemic patients. Gout and Nucleic Acid Metabolism 2002; 26: 25-32.
8. Daskalopoulou SS. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66 (4): 1714-5.
9. Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007;14: 17: 1879-86.
10. De Rosa ML, Cardace P, Rossi M, et al. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002; 16(2): 133-40.
11. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-11.
12. Foley RJ, Weiman EJ. Urate nephropathy. Review. am J Med Sci 1984; 288(5): 208-11.
13. Ford ES, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115:2526-32.
14. France LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-54.
15. Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41: 793-7.
16. Johnson RJ, Kivlighn SD, Kim Y-G, et al. Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225-34.
17. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulindependent diabetes mellitus. Stroke 1998; 29: 635-9.
18. Leonetti G. Comparison of metabolic and hemodynamic effects of hydrochlorothiazide in monotherapy and in association with lisinopril. An Italian multicenter study. Minerva Cardioangiol 1995; 43(9): 389-98.
19. Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002; 20: 347.
20. López-Suárez A, Elvira-González J, Bascuñana-Quirell A, et al. Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome. Med Clin (Barc) 2006; 126: 321-4.
21. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998; 32(6): 917-33.
22. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000; 22: 1186-203.
23. Masako F, Toshihiro H. Mechanism of angiotensin II receptor antagonist losartan on uric acid metabolism. Gout and Nucleic Acid Metabolism 2000; 24: 31-7.
24. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressureindependent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-7.
25. Messerli FH, Frohlich E, Dreslinski GR, et al. Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med 1980; 93(6): 817-21.
26. Milionis H, Kakafika A. Effects of Statin Treatment on Uric Acid Homeostasis in Patients With Primary Hyperlipidemia. Am Heart J 2004; 148(4): 635-40.
27. Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors// The Hypertension Detection and Followup Program Cooperative Research Group. Prev Med 1985; 14(3): 312-35.
28. Nakagawa T, Tuttle K, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005; 1: 80-6.
29. Owens P, Kelly L, Nallen R, et al. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide — a randomized controlled trial. J Hypertens 2000; 18: 339-45.
30. Puig J, Martínez M. Hyperuricemia, Gout, and the Metabolic Syndrome Curr Opin Rheumatol 2008; 20(2): 187-91.
31. Puig JG, Mateos F, Buno A, et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17: 1033-9.
32. Quarantino CP, Di Sci acio N, Rucci C, et al. The normal range of serum urate levels and of fractional urate excretion. Adv Exp Med Biol 1994; 370: 91-3
33. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003; 17(5-6): 397-414.
34. Ruilope LM, Garcia-Puig J. Hyperuricemia and Renal Function//Current Hypertension Reports 2001; 3:197-202.
35. Shahinfar S, Simpson R, Carides A, et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.
36. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879-85.
37. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002; 11: 475-82.
38. Soffer BA, Wright JT, Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7.
39. Steele TH. Hyperuricemic nephropathies. Nephron 1999; 81 Suppl 1: 45-9.
40. Takahashi S, Moriwaki Y. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572-5.
41. Tsouli S, Liberopoulos E. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 10: 1293-301.
42. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991; 59: 364-8.
43. Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 2002; 29: 1950-3.
44. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-8.
45. Würzner G. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2002; 20(2):347.
46. Бугаева Н.В., Балкаров И.М. Артериальная гипертония и нарушение пуринового обмена. Тер архив 1996; 68: 36-9.
47. Глезер М.Г., Бойко Н.В., Абилъдинова А.Ж., Соболев К.Э. Факторы риска у московской популяции больных с артериальной гипертонией. РКЖ 2002; 6: 16-23.
48. Джанашия П.Х., Диденко В.А Является ли гиперурикемия компонентом метаболического синдрома? РКЖ 2001; 1: 15-9.
49. Донсков А.С., Балкаров И.М., Дадина З.М. и др. Уратное поражение почек и метаболические сдвиги у пациентов с артериальной гипертонией. Тер архив 1999; 6: 53-6.
50. Дроздов В.Н. Обмен мочевой кислоты у больных гипертонической болезнью с метаболическим синдромом: Автореф дис канд мед наук. Москва 1999.
51. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мальто А.С. Мочевая кислота — ключевой компонент кардиоренометаболического континуума. Кардиоваск тер профил 2008; 4: 95-106.
Review
For citations:
Nedogoda S.V., Chumachok E.V., Ledyaeva A.A., Tsoma V.V. Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension. Cardiovascular Therapy and Prevention. 2011;10(6):24-29. (In Russ.) https://doi.org/10.15829/1728-8800-2011-6-24-29
Views:
828
Email this article 
